Skip to main contentSkip to footer

Exciting news for Australian medtech!

Exciting news for Australian medtech!

Synthesis Capital has closed close to $60 million for its debut fund targeting early stage health and medical technology startups, with superannuation giant HESTA as its major investor.

Led by the team behind the MedTech Actuator accelerator, the Melbourne-based VC firm brings deep relationships across Australian research institutions, universities and hospitals. The fund will invest between $200,000 and $2 million per company and will have first right of refusal on startups emerging from the MedTech Actuator program.

As the article notes, Australian breakthrough companies are rarely limited by science. They are far more often limited by access to capital, capability and networks. Funds like this one are exactly what the ecosystem needs.

#MedTech #HealthTech #VentureCapital #HealthInnovation #PulseEconomics Medical Technology Association of Australia (MTAA) Teneille Murray Oona Reardon

https://lnkd.in/gNR2fuX2

Read the LinkedIn post

Previous Post
On Wednesday I had the privilege of attending the Medical Technology Association of Australia (MTAA) Women in MedTech Summit, Sydney.
Next Post
Thank you to everyone who supported us for the Bloody Long Walk on Sunday 23rd August.